Literature DB >> 11721754

Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients.

J E Richter1, P J Kahrilas, S J Sontag, T O Kovacs, B Huang, J L Pencyla.   

Abstract

OBJECTIVE: This randomized, double-blind, multicenter study was conducted to confirm a previous finding that lansoprazole relieves heartburn faster than omeprazole in patients with erosive esophagitis.
METHODS: A total of 3510 patients with erosive esophagitis and at least one episode of moderate to very severe daytime and/or nighttime heartburn during the 3 days immediately before the screening visit were randomized to lansoprazole 30 mg once daily or omeprazole 20 mg once daily for 8 wk. Patients recorded the presence and severity of daytime and nighttime heartburn in daily diaries. On treatment days 1-4, patients were telephoned to confirm the completion of their daily diary. The primary efficacy parameters were the percentage of heartburn-free days and heartburn-free nights, as well as the average severity of daytime and nighttime heartburn.
RESULTS: During treatment day I and all evaluation time points including the entire 8-wk treatment period, significantly (p < 0.05) higher percentages of patients treated with lansoprazole than those treated with omeprazole did not experience a single episode of heartburn. Onset of heartburn relief was more rapid in lansoprazole-treated versus omeprazole-treated patients: on day 1, 33% versus 25% of lansoprazole- versus omeprazole-treated patients were heartburn-free. The percentages of heartburn-free days and heartburn-free nights were also significantly (p < 0.01) greater for patients treated with lansoprazole at all evaluation time points. Heartburn severity was significantly less among those treated with lansoprazole compared with omeprazole. Both treatments were safe and well tolerated.
CONCLUSIONS: Over 8 wk, lansoprazole 30 mg once daily relieved heartburn symptoms faster and more effectively than omeprazole 20 mg once daily in patients with erosive esophagitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11721754     DOI: 10.1111/j.1572-0241.2001.05263.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

1.  Gastro-oesophageal reflux disease: symptoms, erosions, and Barrett's--what is the interplay?

Authors:  P Sharma
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 2.  Treatment of uncomplicated reflux disease.

Authors:  Joachim Labenz; Peter Malfertheiner
Journal:  World J Gastroenterol       Date:  2005-07-28       Impact factor: 5.742

3.  Gastroesophageal reflux disease and physical activity.

Authors:  Pawel Jozkow; Dorota Wasko-Czopnik; Marek Medras; Leszek Paradowski
Journal:  Sports Med       Date:  2006       Impact factor: 11.136

4.  Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology.

Authors:  Shobna J Bhatia; Govind K Makharia; Philip Abraham; Naresh Bhat; Ajay Kumar; D Nageshwar Reddy; Uday C Ghoshal; Vineet Ahuja; G Venkat Rao; Krishnadas Devadas; Amit K Dutta; Abhinav Jain; Saurabh Kedia; Rohit Dama; Rakesh Kalapala; Jose Filipe Alvares; Sunil Dadhich; Vinod Kumar Dixit; Mahesh Kumar Goenka; B D Goswami; Sanjeev K Issar; Venkatakrishnan Leelakrishnan; Mohandas K Mallath; Philip Mathew; Praveen Mathew; Subhashchandra Nandwani; Cannanore Ganesh Pai; Lorance Peter; A V Siva Prasad; Devinder Singh; Jaswinder Singh Sodhi; Randhir Sud; Jayanthi Venkataraman; Vandana Midha; Amol Bapaye; Usha Dutta; Ajay K Jain; Rakesh Kochhar; Amarender S Puri; Shivram Prasad Singh; Lalit Shimpi; Ajit Sood; Rajkumar T Wadhwa
Journal:  Indian J Gastroenterol       Date:  2019-12-05

Review 5.  Lansoprazole for maintenance of remission of erosive oesophagitis.

Authors:  James W Freston; Robert L Jackson; Bidan Huang; E David Ballard
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis.

Authors:  Colin W Howden; E David Ballard; Weining Robieson
Journal:  Clin Drug Investig       Date:  2002       Impact factor: 2.859

Review 7.  The role of proton pump inhibitors in gastro-oesophageal reflux disease.

Authors:  Roy Dekel; Chad Morse; Ronnie Fass
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Unmet Needs in the Treatment of Gastroesophageal Reflux Disease.

Authors:  Ram Dickman; Carla Maradey-Romero; Rachel Gingold-Belfer; Ronnie Fass
Journal:  J Neurogastroenterol Motil       Date:  2015-07-30       Impact factor: 4.924

9.  Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis.

Authors:  Thomas O Kovacs; James W Freston; Marian M Haber; Barbara Hunt; Stuart Atkinson; David A Peura
Journal:  Dig Dis Sci       Date:  2009-03-07       Impact factor: 3.199

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.